Telix Pharmaceuticals (TLX) Cash & Equivalents (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Cash & Equivalents data on file, last reported at $141.9 million in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $141.9 million, down 69.46% year-over-year; the trailing twelve-month figure through Dec 2025 was $141.9 million (down 69.46% YoY), and the FY2025 annual result was $141.9 million, down 67.76% from the prior year.
• Cash & Equivalents slipped to $141.9 million in Q4 2025 per TLX's latest filing, from $464.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $464.5 million in Q4 2024 and troughed at $80.2 million in Q4 2023.
• A 3-year average of $228.9 million and a median of $141.9 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents jumped 479.03% in 2024, then sank 69.46% in 2025.
• A 3-year view of Cash & Equivalents shows it stood at $80.2 million in 2023, then jumped by 479.03% to $464.5 million in 2024, then slumped by 69.46% to $141.9 million in 2025.
• Business Quant data shows TLX's Cash & Equivalents at $141.9 million in Q4 2025, $464.5 million in Q4 2024, and $80.2 million in Q4 2023.